DOCSLIB.ORG

Vol. 79 Tuesday, No. 9 January 14, 2014 Pages 2359–2580

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Vol. 79 Tuesday, No. 9 January 14, 2014 Pages 2359–2580 Vol. 79 Tuesday, No. 9 January 14, 2014 Pages 2359–2580 OFFICE OF THE FEDERAL REGISTER VerDate Mar 15 2010 19:13 Jan 13, 2014 Jkt 232001 PO 00000 Frm 00001 Fmt 4710 Sfmt 4710 E:\FR\FM\14JAWS.LOC 14JAWS emcdonald on DSK67QTVN1PROD with NOTICES4 II Federal Register / Vol. 79, No. 9 / Tuesday, January 14, 2014 The FEDERAL REGISTER (ISSN 0097–6326) is published daily, SUBSCRIPTIONS AND COPIES Monday through Friday, except official holidays, by the Office PUBLIC of the Federal Register, National Archives and Records Administration, Washington, DC 20408, under the Federal Register Subscriptions: Act (44 U.S.C. Ch. 15) and the regulations of the Administrative Paper or fiche 202–512–1800 Committee of the Federal Register (1 CFR Ch. I). The Assistance with public subscriptions 202–512–1806 Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402 is the exclusive distributor of the official General online information 202–512–1530; 1–888–293–6498 edition. Periodicals postage is paid at Washington, DC. Single copies/back copies: The FEDERAL REGISTER provides a uniform system for making Paper or fiche 202–512–1800 available to the public regulations and legal notices issued by Assistance with public single copies 1–866–512–1800 Federal agencies. These include Presidential proclamations and (Toll-Free) Executive Orders, Federal agency documents having general FEDERAL AGENCIES applicability and legal effect, documents required to be published Subscriptions: by act of Congress, and other Federal agency documents of public interest. Paper or fiche 202–741–6005 Documents are on file for public inspection in the Office of the Assistance with Federal agency subscriptions 202–741–6005 Federal Register the day before they are published, unless the issuing agency requests earlier filing. For a list of documents currently on file for public inspection, see www.ofr.gov. The seal of the National Archives and Records Administration authenticates the Federal Register as the official serial publication established under the Federal Register Act. Under 44 U.S.C. 1507, the contents of the Federal Register shall be judicially noticed. The Federal Register is published in paper and on 24x microfiche. It is also available online at no charge at www.fdsys.gov, a service of the U.S. Government Printing Office. The online edition of the Federal Register is issued under the authority of the Administrative Committee of the Federal Register as the official legal equivalent of the paper and microfiche editions (44 U.S.C. 4101 and 1 CFR 5.10). It is updated by 6:00 a.m. each day the Federal Register is published and includes both text and graphics from Volume 59, 1 (January 2, 1994) forward. For more information, contact the GPO Customer Contact Center, U.S. Government Printing Office. Phone 202-512-1800 or 866-512-1800 (toll free). E-mail, gpocusthelp.com. The annual subscription price for the Federal Register paper edition is $749 plus postage, or $808, plus postage, for a combined Federal Register, Federal Register Index and List of CFR Sections Affected (LSA) subscription; the microfiche edition of the Federal Register including the Federal Register Index and LSA is $165, plus postage. Six month subscriptions are available for one-half the annual rate. The prevailing postal rates will be applied to orders according to the delivery method requested. The price of a single copy of the daily Federal Register, including postage, is based on the number of pages: $11 for an issue containing less than 200 pages; $22 for an issue containing 200 to 400 pages; and $33 for an issue containing more than 400 pages. Single issues of the microfiche edition may be purchased for $3 per copy, including postage. Remit check or money order, made payable to the Superintendent of Documents, or charge to your GPO Deposit Account, VISA, MasterCard, American Express, or Discover. Mail to: U.S. Government Printing Office—New Orders, P.O. Box 979050, St. Louis, MO 63197-9000; or call toll free 1- 866-512-1800, DC area 202-512-1800; or go to the U.S. Government Online Bookstore site, see bookstore.gpo.gov. There are no restrictions on the republication of material appearing in the Federal Register. How To Cite This Publication: Use the volume number and the page number. Example: 77 FR 12345. Postmaster: Send address changes to the Superintendent of Documents, Federal Register, U.S. Government Printing Office, Washington, DC 20402, along with the entire mailing label from the last issue received. VerDate Mar 15 2010 19:13 Jan 13, 2014 Jkt 232001 PO 00000 Frm 00002 Fmt 4710 Sfmt 4710 E:\FR\FM\14JAWS.LOC 14JAWS emcdonald on DSK67QTVN1PROD with NOTICES4 III Contents Federal Register Vol. 79, No. 9 Tuesday, January 14, 2014 Agriculture Department Community Development Financial Institutions Fund See Forest Service NOTICES See Rural Utilities Service Agency Information Collection Activities; Proposals, Submissions, and Approvals, 2509 Alcohol and Tobacco Tax and Trade Bureau PROPOSED RULES Comptroller of the Currency Viticultural Areas: NOTICES Manton Valley; Establishment, 2399–2404 Agency Information Collection Activities; Proposals, Submissions, and Approvals, 2509–2535 Bureau of Consumer Financial Protection PROPOSED RULES Defense Department Debt Collection (Regulation F), 2384 NOTICES Meetings: Census Bureau National Commission on the Structure of the Air Force, NOTICES 2427–2428 Agency Information Collection Activities; Proposals, Submissions, and Approvals: Defense Nuclear Facilities Safety Board Monthly Wholesale Trade Survey, 2409 NOTICES Extension of Hearing Record Closure Date, 2428 Centers for Disease Control and Prevention NOTICES Meetings: Drug Enforcement Administration Breast and Cervical Cancer Early Detection and Control NOTICES Advisory Committee, 2444 Decisions and Orders: James Clopton, M.D., 2475–2478 Children and Families Administration NOTICES Education Department Agency Information Collection Activities; Proposals, NOTICES Submissions, and Approvals, 2444–2446 Agency Information Collection Activities; Proposals, Reallotment of FY 2013 Funds: Submissions, and Approvals: Low Income Home Energy Assistance Program, 2446 Teacher Quality Enhancement Grants Program’s Scholarship Contract and Teaching Verification Form Coast Guard for Title II Scholarship Recipients, 2428–2429 RULES Anchorage Grounds and Safety Zones: Energy Department Delaware River; Marcus Hook, PA, 2371–2375 See Federal Energy Regulatory Commission NOTICES PROPOSED RULES Draft Guidance for Industry: Energy Conservation Standards for Commercial/Industrial Interpreting Regulations for Marine Casualty Reporting, Pumps: 2466–2467 Meetings; Appliance Standards and Rulemaking Federal Guidance for Industry: Advisory Committee Commercial/Industrial Pumps Distant Water Tuna Fleet Vessels Manning Exemption Working Group, 2383–2384 Guidance, 2464–2466 NOTICES Waterway Suitability Assessment for Construction and Applications to Export Electric Energy: Operation of Liquefied Gas Terminals: Global Pure Energy, LLC, 2429–2430 Lake Charles, LA, 2467–2468 Great Bay Energy VI, LLC, 2429 Commerce Department Environmental Protection Agency See Census Bureau RULES See Foreign-Trade Zones Board Air Quality State Implementation Plans; Revisions: See International Trade Administration California; El Dorado County Air Quality Management See National Oceanic and Atmospheric Administration District, 2375–2377 PROPOSED RULES Commodity Futures Trading Commission Air Quality State Implementation Plans; Revisions: RULES California; El Dorado County Air Quality Management Cross-References to Bank Secrecy Act Regulations, 2370– District, 2404–2405 2371 Permits: PROPOSED RULES Federal Minor New Source Review Program in Indian Aggregation of Provisions, 2394–2395 Country, 2546–2573 NOTICES NOTICES Meetings; Sunshine Act, 2427 2018 Emissions Modeling Platform; Availability, 2437–2441 VerDate Mar<15>2010 19:12 Jan 13, 2014 Jkt 232001 PO 00000 Frm 00001 Fmt 4748 Sfmt 4748 E:\FR\FM\14JACN.SGM 14JACN emcdonald on DSK67QTVN1PROD with NOTICES3 IV Federal Register / Vol. 79, No. 9 / Tuesday, January 14, 2014 / Contents Agency Information Collection Activities; Proposals, Federal Energy Regulatory Commission Submissions, and Approvals: NOTICES Notification of Episodic Releases of Oil and Hazardous Applications: Substances, 2441 Panhandle Eastern Pipe Line Co., LP, 2430–2431 Permits: Combined Filings, 2431–2435 Shell; Discoverer Drill Ship and the Kulluk Conical Complaints: Drilling Unit; Termination, 2442 Southwest Airlines Co., and United Airlines, Inc. v. Colonial Pipeline Co., 2435 Filings: Executive Office for Immigration Review Anaheim, CA, 2436 NOTICES Azusa, CA, 2435 Agency Information Collection Activities; Proposals, Colton, CA, 2435–2436 Submissions, and Approvals: Meetings; Sunshine Act, 2436–2437 Request by Organization for Accreditation of Non- Petitions for Waivers: Attorney, 2478–2479 Koch Pipeline Company, LP, 2437 Executive Office of the President Federal Highway Administration See Presidential Documents NOTICES Environmental Impact Statements; Availability, etc.: Jefferson County, WV, 2504–2505 Federal Aviation Administration RULES Federal Maritime Commission Airworthiness Directives: NOTICES Eurocopter France Helicopters, 2366–2368 Meetings; Sunshine Act, 2442–2443 IFR Altitudes, 2368–2370 Special Conditions: Federal Motor Carrier Safety Administration Airbus, A350–900 Series Airplane; Design Roll RULES Maneuver, 2365–2366 Medical Certification Requirements as Part of the Airbus, Model A350–900 Series
Load more

Recommended publications
  • Triptans Step Therapy/Quantity Limit Criteria
    Triptans Step Therapy/Quantity Limit Criteria Program may be implemented with the following options 1) step therapy 2) quantity limits or 3) step therapy with quantity limits For Blue Cross and Blue Shield of Illinois Option 1 (step therapy only) will apply. Brand Generic Dosage Form Amerge® naratriptan tablets Axert® almotriptan tablets Frova® frovatriptan tablets Imitrex® sumatriptan injection*, nasal spray, tablets* Maxalt® rizatriptan tablets Maxalt-MLT® rizatriptan tablets Relpax® eletriptan tablets Treximet™ sumatriptan and naproxen tablets Zomig® zolmitriptan tablets, nasal spray Zomig-ZMT® zolmitriptan tablets * generic available and included as target agent in quantity limit edit FDA APPROVED INDICATIONS1-7 The following information is taken from individual drug prescribing information and is provided here as background information only. Not all FDA-approved indications may be considered medically necessary. All criteria are found in the section “Prior Authorization Criteria for Approval.” Amerge® Tablets1, Axert® Tablets2, Frova® Tablets3,Imitrex® injection4, Imitrex Nasal Spray5, Imitrex Tablets6, Maxalt® Tablets7, Maxalt-MLT® Tablets7, Relpax® Tablets8, Treximet™ Tablets9, Zomig® Tablets10, Zomig-ZMT® Tablets10, and Zomig® Nasal Spray11 Amerge (naratriptan), Axert (almotriptan), Frova (frovatriptan), Imitrex (sumatriptan), Maxalt (rizatriptan), Maxalt-MLT (rizatriptan orally disintegrating), Relpax (eletriptan), Treximet (sumatriptan/naproxen), Zomig (zolmitriptan), and Zomig-ZMT (zolmitriptan orally disintegrating) tablets, and Imitrex (sumatriptan) and Zomig (zolmitriptan) nasal spray are all indicated for the acute treatment of migraine attacks with or without aura in adults. They are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. Safety and effectiveness of all of these products have not been established for cluster headache, which is present in an older, predominantly male population.
    [Show full text]
  • Medication Guide 2012
    DeKalb County D.U.I. Court Supervised Treatment Program MEDICATION GUIDE Medication Guide 2012 DeKalb County State Court Decatur, Georgia xxi ********** WELCOME TO THE DEKALB COUNTY D.U.I. COURT SUPERVISED TREATMENT PROGRAM. This 2012 Medication Guide was developed as a collaborative effort by Becky Pirouz, Pharm.D., Director of Pharmacy, Peachford Hospital, and by Lois Michalove, Treatment Coordinator for the DeKalb County D.U.I. Court Supervised Treatment Program, both of whom have extensive experience in addiction recovery and treatment. ********** The following information is intended to assist you in making decisions about medications. This may include those medications that you are prescribed and/or your selection of over-the-counter (OTC) products. Unintended exposure may compromise your treatment program. This is not an exhaustive list, but contains some of the medications that are most commonly used. If in doubt, always consult the Treatment Coordinator. Please inform your physician, dentist, pharmacist and other health care professionals that you are in a recovery program. WE ARE A ZERO-TOLERANCE PROGRAM! DO NOT COMPROMISE YOUR RECOVERY BY MAKING HIGH-RISK CHOICES! xxii - Section 1 – Drugs To Avoid The following drugs must not be used at any time. They are well known to be abused and even small amounts may result in relapse and are contraindicated in your treatment program. However, extenuating circumstances may occur which necessitates the short- term limited use of some of the drugs on this list in consultation with your physician, the Judge and the Treatment Coordinator. This decision should be made prior to your ingestion of any of the Drugs to Avoid.
    [Show full text]
  • Guideline for Preoperative Medication Management
    Guideline: Preoperative Medication Management Guideline for Preoperative Medication Management Purpose of Guideline: To provide guidance to physicians, advanced practice providers (APPs), pharmacists, and nurses regarding medication management in the preoperative setting. Background: Appropriate perioperative medication management is essential to ensure positive surgical outcomes and prevent medication misadventures.1 Results from a prospective analysis of 1,025 patients admitted to a general surgical unit concluded that patients on at least one medication for a chronic disease are 2.7 times more likely to experience surgical complications compared with those not taking any medications. As the aging population requires more medication use and the availability of various nonprescription medications continues to increase, so does the risk of polypharmacy and the need for perioperative medication guidance.2 There are no well-designed trials to support evidence-based recommendations for perioperative medication management; however, general principles and best practice approaches are available. General considerations for perioperative medication management include a thorough medication history, understanding of the medication pharmacokinetics and potential for withdrawal symptoms, understanding the risks associated with the surgical procedure and the risks of medication discontinuation based on the intended indication. Clinical judgement must be exercised, especially if medication pharmacokinetics are not predictable or there are significant risks associated with inappropriate medication withdrawal (eg, tolerance) or continuation (eg, postsurgical infection).2 Clinical Assessment: Prior to instructing the patient on preoperative medication management, completion of a thorough medication history is recommended – including all information on prescription medications, over-the-counter medications, “as needed” medications, vitamins, supplements, and herbal medications. Allergies should also be verified and documented.
    [Show full text]
  • UCSF UC San Francisco Electronic Theses and Dissertations
    UCSF UC San Francisco Electronic Theses and Dissertations Title Deep phenotypic profiling of neuroactive drugs in larval zebrafish Permalink https://escholarship.org/uc/item/3vk1d0gr Author Gendelev, Leo Publication Date 2019 Peer reviewed|Thesis/dissertation eScholarship.org Powered by the California Digital Library University of California Deep phenotypic profiling of neuro-active drugs in larval Zebrafish by Lev Gendelev DISSERTATION Submitted in partial satisfaction of the requirements for degree of DOCTOR OF PHILOSOPHY in Biophysics in the GRADUATE DIVISION of the UNIVERSITY OF CALIFORNIA, SAN FRANCISCO Approved: ______________________________________________________________________________Michael Keiser Chair ______________________________________________________________________________DAVID KOKEL ______________________________________________________________________________Jim Wells ______________________________________________________________________________ ______________________________________________________________________________ Committee Members Copyright 2019 by Lev (Leo) Gendelev ii In Loving Memory of My Mother, Lucy Gendelev iii Acknowledgements First of all, I thank my advisor, Michael Keiser, for his unwavering support through the most difficult of times. I will above all else reminisce over our brainstorming sessions, where my half- wrought white-board scribbles were met with enthusiasm and sometimes even developed into exciting side-projects. My PhD experience felt less like work and more like a fantastical scientific
    [Show full text]
  • Triptan Therapy for Acute Migraine
    Triptan Therapy for Acute Migraine Headache John Farr Rothrock, MD University of Alabama at Birmingham, Birmingham, AL Deborah I. Friedman, MD, MPH University of Texas Southwestern, Dallas, TX The “triptans” are 5HT-1B/1D receptor agonists that were developed to treat acute migraine and acute cluster headache. Sumatriptan, the original triptan preparation, has been in general use since 1993, so there has been considerable experience with triptans over time. There are currently seven oral triptans on the market in the United States: sumatriptan (Imitrex™), naratriptan (Amerge™), zolmitriptan (Zomig™), rizatriptan (Maxalt™), almotriptan (Axert™), frovatriptan (Frova™), and eletriptan (Relpax™); brand names may differ by country. There is also a combination preparation of oral sumatriptan/naproxen (Treximet™). Two triptans (sumatriptan, zolmitriptan) are marketed as nasal sprays, and sumatriptan is available for subcutaneous injection, including a needle-free subcutaneous delivery system (Sumavel™). Sumatriptan suppositories are marketed in Europe but not in North America. Zolmitriptan and rizatriptan are sold in an oral disintegrating tablet or “melt” formulation as well as in tablet form; while the “melt” formulations may be more convenient (no liquid is required to propel them into the stomach), they are absorbed similarly to regular tablets and there is no evidence to suggest that they work faster than the tablet formulations. Some patients with migraine-associated nausea prefer the disintegrating tablets while others cannot tolerate their taste. Although all of the triptans initially were investigated for the treatment of migraine headache of moderate to severe intensity and were superior to placebo in those pivotal trials, they appear to be more consistently effective when used to treat migraine earlier in the attack, when the headache is still mild to moderate.
    [Show full text]
  • Engineered Cells for Production of Indole-Derivatives
    Downloaded from orbit.dtu.dk on: Oct 05, 2021 Engineered cells for production of indole-derivatives Kell, Douglas; Yang, Lei; Malla, Sailesh Publication date: 2020 Document Version Publisher's PDF, also known as Version of record Link back to DTU Orbit Citation (APA): Kell, D., Yang, L., & Malla, S. (2020). Engineered cells for production of indole-derivatives. (Patent No. WO2020187739). General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. Users may download and print one copy of any publication from the public portal for the purpose of private study or research. You may not further distribute the material or use it for any profit-making activity or commercial gain You may freely distribute the URL identifying the publication in the public portal If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. ) ( 2 (51) International Patent Classification: C07K 14/715 (2006.01) (21) International Application Number: PCT/EP2020/056828 (22) International Filing Date: 13 March 2020 (13.03.2020) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 19163 184.5 15 March 2019 (15.03.2019) EP (71) Applicant: DANMARKS TEKNISKE UNIVERSITET [DK/DK]; Anker Engelunds Vej 101 A, 2800 Kgs. Lyngby (DK). (72) Inventors: KELL, Douglas, Bruce; Chirk Manor, Trevor Rd, Chirk, Wrexham LL14 5HD (GB).
    [Show full text]
  • Recreational Use, Analysis and Toxicity of Tryptamines
    Send Orders for Reprints to [email protected] 26 Current Neuropharmacology, 2015, 13, 26-46 Recreational Use, Analysis and Toxicity of Tryptamines Roberta Tittarelli1, Giulio Mannocchi1, Flaminia Pantano1 and Francesco Saverio Romolo1,2,* 1Legal Medicine Section, Department of Anatomical, Histological, Forensic Medicine and Orthopedic Sciences, “Sapienza” University of Rome, Viale Regina Elena, 336, 00161 Rome, Italy; 2Institut de Police Scientifique, Université de Lausanne, Batochime, 1015 Lausanne, Switzerland Abstract: The definition New psychoactive substances (NPS) refers to emerging drugs whose chemical structures are similar to other psychoactive compounds but not identical, representing a “legal” alternative to internationally controlled drugs. There are many categories of NPS, such as synthetic cannabinoids, synthetic cathinones, phenylethylamines, piperazines, ketamine derivatives and tryptamines. Tryptamines are naturally occurring compounds, which can derive from the amino acid tryptophan by several biosynthetic pathways: their structure is a combination of a benzene ring Roberta Tittarelli and a pyrrole ring, with the addition of a 2-carbon side chain. Tryptamines include serotonin and melatonin as well as other compounds known for their hallucinogenic properties, such as psilocybin in ‘Magic mushrooms’ and dimethyltryptamine (DMT) in Ayahuasca brews. Aim: To review the scientific literature regarding tryptamines and their derivatives, providing a summary of all the available information about the structure of these compounds, their effects in relationship with the routes of administration, their pharmacology and toxicity, including articles reporting cases of death related to intake of these substances. Methods: A comprehensive review of the published scientific literature was performed, using also non peer-reviewed information sources, such as books, government publications and drug user web fora.
    [Show full text]
  • Triptans in the Treatment of Migraine in Adults
    The role of triptans in the treatment of migraine in adults 28 Paracetamol or a non-steroidal anti-inflammatory drug (NSAID) can be used first-line for pain relief in acute migraine. A triptan can then be trialled if this was not successful. Combination treatment with a triptan and paracetamol or NSAID may be required for some patients. Most triptans are similarly effective, so choice is usually based on formulation, e.g. a non-oral preparation may be more suitable for patients with nausea or vomiting. To avoid medication overuse headache, triptan use should not exceed ten or more days per month. Migraine is a condition characterised by attacks of moderate A stepwise approach to managing migraine: to severe, throbbing headache, which is usually unilateral. This triptans are appropriate at step two is often associated with other symptoms, including nausea, vomiting, photophobia or phonophobia. Approximately one- There are a number of treatment guidelines for acute migraine, third of patients with migraines also experience a preceding all of which differ slightly in their recommended approach (see aura. Worldwide, approximately one in every seven people the NICE and BASH guidelines).3, 4 Most algorithms, however, are affected by migraines, which are often associated with recommend stepwise treatment, with triptans usually tried significant personal and socioeconomic impact.1 In the Global after paracetamol and NSAIDs. Burden of Disease Survey 2010, migraine was ranked as the third most prevalent disorder and the seventh-highest specific A reasonable approach is: 2 cause of disability. Step 1: Over-the-counter analgesics (paracetamol, NSAIDs) Step 2: Triptan For information on diagnosing migraine, see: Step 3: Combination treatment with a triptan and an NSAID National Institute for Health and Care Excellence (NICE) +/- anti-emetic (prochlorperazine, metoclopramide) at Guideline: Headaches.
    [Show full text]
  • Cyclisation of Indoles by Using Orthophosphoric Acid in Sumatriptan and Rizatriptan
    Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research, 2013, 5(8):107-109 ISSN : 0975-7384 Research Article CODEN(USA) : JCPRC5 Cyclisation of indoles by using orthophosphoric acid in sumatriptan and rizatriptan K. Sudarshan Rao, K. Nageswara Rao, Bhausaheb Chavan, P. Muralikrishna and A. Jayashree Centre for Chemical Sciences and Technology, IST, Jawaharlal Nehru Technological University, Kukatpally, Hyderabad, Andhra Pradesh, India _____________________________________________________________________________________________ ABSTRACT A simple and Novel improved process for the preparation of pure Sumatriptan and Rizatriptan, the cyclisation of indole ring by the using of ortho phosphoric acid. The present work describes the detection, origin, synthesis, characterization and providing a commercial method to synthesize Sumatriptan and Rizatriptan. The procedure developed has several advantages such as mild reaction conditions, convenient operations and easily obtained materials. The synthetic method is suitable for industrial manufacture. Keywords: Cyclisation, Sumatriptan, Rizatriptan, ortho phosphoric acid, _____________________________________________________________________________________________ INTRODUCTION Triptans are a family of tryptamine-based drugs used as abortive medication in the treatment of migraines and cluster headaches. They were first introduced in the 1990s. While effective at treating individual headaches, they do not provide preventative treatment and are not considered a cure. The first triptan (i.e., tryptamine derivative) to be marketed for the acute treatment of migraine, sumatriptan, has been so successful that a number of second generation triptans are now marketed or in the late stages of clinical development 1,2 . The triptans represent a breakthrough in acute migraine treatment, being far more selective for 5-HT1B-1D receptors than their relatively nonselective predecessor’s ergotamine and dihydroergotamine (DHE) 3,4 .
    [Show full text]
  • Download Leaflet View the Patient Leaflet in PDF Format
    Package leaflet: Information for the user MAXALT® 10 mg Tablets/5 mg Tablets rizatriptan Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. Keep this leaflet. You may need to read it again. If you have further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What MAXALT is and what it is used for 2. What you need to know before you take MAXALT 3. How to take MAXALT 4. Possible side effects 5. How to store MAXALT 6. Contents of the pack and other information 1. What MAXALT is and what it is used for MAXALT belongs to a class of medicines called selective serotonin 5-HT1B/1D receptor agonists. MAXALT is used to treat the headache phase of the migraine attack in adults. Treatment with MAXALT: Reduces swelling of blood vessels surrounding the brain. This swelling results in the headache pain of a migraine attack. 2. What you need to know before you take MAXALT Do not take MAXALT if: you are allergic to rizatriptan benzoate or any of the other ingredients of this medicine (listed in section 6) you have moderately severe or severe high blood pressure or mild high blood pressure that is not controlled by medication you have or have ever had heart problems
    [Show full text]
  • MAXALT® (Max-Awlt) and MAXALT-MLT® Rizatriptan Benzoate Tablets and Orally Disintegrating Tablets
    Patient Information MAXALT® (max-awlt) and MAXALT-MLT® rizatriptan benzoate Tablets and Orally Disintegrating Tablets Read this Patient Information before you start taking MAXALT® and each time you get a refill. There may be new information. This information does not take the place of talking to your doctor about your medical condition or your treatment. Unless otherwise stated, the information in this Patient Information leaflet applies to both MAXALT Tablets and to MAXALT-MLT® Orally Disintegrating Tablets. What is MAXALT? MAXALT is a prescription medicine that belongs to a class of medicines called Triptans. MAXALT is available as a traditional tablet (MAXALT) and as an orally disintegrating tablet (MAXALT-MLT). MAXALT and MAXALT-MLT are used to treat migraine attacks with or without aura in adults and in children 6 to 17 years of age. MAXALT is not to be used to prevent migraine attacks. MAXALT is not for the treatment of hemiplegic or basilar migraines. It is not known if MAXALT is safe and effective for the treatment of cluster headaches. It is not known if taking more than 1 dose of MAXALT in 24 hours is safe and effective in children 6 to 17 years of age. It is not known if MAXALT is safe and effective in children under 6 years of age. Who should not take MAXALT? Do not take MAXALT if you: have or have had heart problems have or have had a stroke or a transient ischemic attack (TIA) have or have had blood vessel problems including ischemic bowel disease have uncontrolled high blood pressure have taken other Triptan medicines in the last 24 hours have taken ergot-containing medicines in the last 24 hours have hemiplegic or basilar migraines take monoamine oxidase (MAO) inhibitor or have taken a MAO inhibitor within the last 2 weeks are allergic to rizatriptan benzoate or any of the ingredients in MAXALT.
    [Show full text]
  • Medication-Guide.Pdf
    Migraine Medication Guide Migraine Medication Guide PREVENTIVE MEDICINES PREVENTIVE MEDICINES Dosing is intended for adults Dosing is intended for adults Migraine Prophylaxis: Level A Pediatric Migraine divalproex/sodium valproate* 500-1000 mg /day Intervention metoprolol 47.5-200 mg/day Analgesics: acetominophen, ibuprofen propranolol* 120-240 mg/day Triptans - FDA approved age 6-17 rizatriptan - weight <40kg (88 lbs), use 5 mg; (candesartan 8-16 mg/day) >40kg (88 lbs) use 10 mg timolol* 10-15 mg/day age 12-17 almotriptan- 6.25-12.5mg PO x1; Max 25/24h; may topiramate* 25-200 mg/day repeat dose x1 after 2h sumatriptan-naproxen sodium 10/60 tab; Max Migraine Prophylaxis: Level B 85/500mg tab per 24h zolmitriptan nasal spray (when nausea or vomiting) - riboavin (vitamin B2) 400 mg/day one 2.5 dose only Off-label use sumatriptan- 25 mg magnesium trimagnesium dicitrate 500-600 mg/day nasal sumatriptan - 5, 10, 25 mg feverfew 50-300 mg q12 zolmitriptan tab and melt tab - 5mg feverfew CO2 extract 2.08-18.75 mg q8 amitriptyline 25-150 mg/day (see below) Menstrual atenolol 100 mg/day (50-200 mg) no FDA approved therapies venlafaxine (ER) -Effexor 150 mg/day (37.5-150 mg) Mild-Moderate symptoms lisinopril 10 mg/day ibuprofen 800 mg every 8-12 hours prn histamine 1-10 mg subc 2x week naproxen 250 mg 1-2 every 8-12 hours prn fenoprofen 200 - 600 mg/day 500 mg every 12 hours prn acetaminophen, aspirin or ibuprofen with or without caffeine ibuprofen 200 mg q12 ketoprofen 50 mg q8 Moderate-Severe symptoms naproxen 500 - 1000 mg/day triptan with or
    [Show full text]